Cure My Disease

Don't miss your cure!

 Log in / Sign up

Nerve block injection may ease migraine drug withdrawal

NCT ID NCT07568496

Symptom relief Sponsor: Mahidol University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a nerve block injection at the back of the head can help people with migraine who overuse painkillers. The injection contains lidocaine and a steroid. 130 participants will receive either the active injection or a placebo. Researchers will track headache days and medication use for 3 months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
lidocaine and methylprednisolone injection
What this could lead to
If it works, this could provide a safe, short-term treatment to help migraine sufferers stop overusing painkillers without severe withdrawal headaches.
What could go wrong
This is an early-stage trial with no phase, and the nerve block may not work better than a placebo. Risks include allergic reactions or injection-site pain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 130 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

May 2026

An estimate. Start dates often move.

Expected to finish

Nov 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients who have a diagnosis of migraine with medication overuse headache according to ICHD-3 criteria confirmed by a neurologist * Female patients will be screened for pregnancy planning and married female patients must undergo a urine pregnancy test Exclusion Criteria: * Patients who have other types of headache disorders other than migraine * Patients who have a previous history of allergy to corticosteroid or lidocaine * Patients who had previous skull surgery * Pregnant women * Patients with a history of uncontrolled depression, or psychosis * Patients who get or plan to get CGRP-targeted therapies or botulinum toxin injection * Patients with an increased risk of bleeding or underlying bleeding disorders

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Greater occipital nerve block are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Headache Disorders, Secondary migraine disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Greater occipital nerve block Medication-overuse headache Migraine disorders

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Faculty of Medicine Siriraj Hospital, Mahidol University

    Bangkok, Bangkok, 10700, Thailand

  • Faculty of Medicine, Chiang Mai University

    Chiang Mai, Chiang Mai, 50200, Thailand

  • Faculty of Medicine, Prince of Songkla University

    Hat Yai, Changwat Songkhla, 90110, Thailand

More trials for these conditions

Other studies related to the condition(s) this trial covers.